Chinese target trial emulation of 2092 adults with stage G3–G4 CKD & asymptomatic hyperuricemia starting ULT. At 3 yrs, renal progression (ESKD or ≥40% eGFR decline) was 33.3% in T2T vs 35.8% in non-T2T (risk ratio 0.93; 0.83–1.08). https://t.co/lAT0noE1uA https://t.co/mFVpvvFcsN

Cochicine overdose still occurs & can be deadly. There is no antidote. From 2011-2021, there were 57 pediatric cases (median 7 yrs)(0.41 /million kids/year. 52% started w/ GI Sxs, 12% multiple organ failure &4 deaths (7%). Ingested doses ranged from 0.01 to 1.45 mg/kg. https://t.co/RULmdBX0Qj

RHEUM SURVEY>> Which Gout drugs lower the risk of cardiovascular death? Answer here: https://t.co/1OY1B3ET7B https://t.co/MRJP5OOtXb

Can achieving serum urate targets do more than prevent flares? Our latest #Gout Journal Club reviews two important studies linking treat-to-target urate-lowering therapy with improved cardiovascular and kidney outcomes—and what the evidence means for clinical practice. Join https://t.co/6QJXfUEvDy

JAMA HBV review - Worldwide, HBV affects ~254 million, causing 1.1 million deaths. In 2022, 14k new HBV infx in the US. HBsAg = ongoing infxn; HBsAb indicates immunity; HBcAg=ongoing or past infection. Do HBV DNA for virus-replication activity https://t.co/Yvdx09DrQ5 https://t.co/88VsTEgFev

EULAR26: Vasculitis updates: Glucorticoid use in AAV and GCA EULAR recommends a combination of glucocorticoids with either rituximab or cyclophosphamide for remission induction in life-threatening or organ-threatening AAV, followed by gradual tapering of glucocorticoids. https://t.co/9HI9SwMSSv

ICYMI: Worldwide Trends in Hyperuricemia A Lancet Rheumatology systematic review shows the prevalence of hyperuricaemia has risen markedly over the past two decades in both men and women, owing to population growth, aging, and increasing age-specific rates. https://t.co/8QAWkka0DM

RheumIQ: Per the 2025 EULAR RA recommendations, if a csDMARD strategy fails, which drug class requires careful risk assessment before use? Test your knowledge this week at https://t.co/z8mLbcgE5D. https://t.co/r61gvyMHPS

2026 Guidelines for the Treatment of Axial Spondyloarthritis New guidelines offer clinicians and patients clearer directions on diagnostic workup, treatment selection, and long-term disease management, while emphasizing shared decision-making due to ongoing evidence gap. https://t.co/3V8bfDptDU

ICYMI: VEXAS Syndrome - A Review Beck et al has published a review of the VEXAS syndrome in The Lancet, focusing on the pathogenesis, spectrum, and treatment strategies. https://t.co/K9IMLBdCGI https://t.co/LJdnRflzsU

EULAR26: GLP-1 Agonist Use in the RISE Registry At EULAR 2026, McCormick and Curtis et al presented data from the American College of Rheumatology’s (ACR) Rheumatology Informatics System for Effectiveness (RISE) registry on the use of GLP-1 agents in rheumatic diseases (RMD). https://t.co/EqgETKjN1v

Insights into Treating Lupus - A Rheum Survey RheumNow recently surveyed clinicians to better understand current practice patterns, educational needs, and barriers to the use of new, advanced therapies in systemic lupus erythematosus (SLE). A total of 197 clinicians completed https://t.co/HNaUK5Q9uq